Valuation: TScan Therapeutics, Inc.

Market Cap 51.89M 45.57M 42.38M 38.89M 73.07M 5B 74.2M 503M 197M 2.46B 195M 191M 8.49B P/E 2026 *
-0.91x
P/E 2027 * -0.86x
Enterprise Value -46.98M -41.26M -38.37M -35.21M -66.16M -4.52B -67.18M -456M -178M -2.22B -176M -173M -7.69B EV / Sales 2026 *
-6.22x
EV / Sales 2027 * -2.93x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -
06-22 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
06-22 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
06-03 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
05-06 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-02 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
03-04 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
02-26 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
02-26 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
12-18 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
12-06 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
11-14 Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight MT
11-12 TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-12 TScan Therapeutics Q3 revenue jumps RE
1 day-6.19%
1 week-13.21%
Current month-18.99%
1 month-9.86%
3 months-36.98%
6 months-30.35%
Current year-20.60%
1 week 0.79
Extreme 0.7904
0.97
1 month 0.79
Extreme 0.7904
1.28
Current year 0.79
Extreme 0.7904
1.47
1 year 0.79
Extreme 0.7904
2.57
3 years 0.79
Extreme 0.7904
9.69
5 years 0.79
Extreme 0.7904
14.71
10 years 0.79
Extreme 0.7904
14.71
Manager TitleAgeSince
Chief Executive Officer 56 2023-03-27
Director of Finance/CFO 57 2024-01-28
Chief Tech/Sci/R&D Officer 50 2024-04-07
Director TitleAgeSince
Director/Board Member 68 2021-03-22
Director/Board Member 56 2023-05-23
Chairman 55 2024-06-11
Date Insider Type Main position Quantity % Market Cap.
5/20/26 Free

Director

67,000 0.1200%
5/20/26 Free

Director

67,000 0.1200%
5/20/26
Baker Bros. Advisors LP
FreeCompany 134,000 0.2400%
Change 5-day change 1-year change 3-year change Capi.($)
-6.19%-13.21%-57.54%-64.39% 51.89M
+0.93%+6.97%+62.83%+67.97% 57.28B
-1.92%+6.03%+43.68%+84.56% 54.99B
-0.46%-1.29%+3.28%+422.58% 23.18B
-2.97%-2.35%-22.03%-16.54% 22.59B
-0.36%+5.73%+30.99%-3.58% 20.46B
-1.34%+0.51%+25.02%-30.27% 17.56B
-1.44%+5.67%+32.54%+544.11% 15.67B
-1.30%-5.02%+165.62%+291.37% 14.46B
-0.50%-0.98%+23.62%+178.38% 13.92B
Average -1.56%-0.17%+30.80%+147.42% 24.02B
Weighted average by Cap. -0.87%+2.09%+41.16%+135.64%

Financials

2026 *2027 *
Net sales 7.56M 6.64M 6.17M 5.66M 10.64M 728M 10.81M 73.3M 28.64M 358M 28.37M 27.76M 1.24B 7.81M 6.86M 6.38M 5.85M 10.99M 752M 11.16M 75.72M 29.58M 370M 29.31M 28.68M 1.28B
Net income -115M -101M -93.99M -86.25M -162M -11.08B -165M -1.12B -436M -5.45B -432M -423M -18.84B -125M -110M -102M -93.55M -176M -12.02B -178M -1.21B -473M -5.91B -469M -458M -20.43B
Net Debt -98.87M -86.83M -80.75M -74.1M -139M -9.52B -141M -959M -375M -4.68B -371M -363M -16.18B -74.76M -65.66M -61.06M -56.03M -105M -7.2B -107M -725M -283M -3.54B -281M -275M -12.24B
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
139
Date Price Change Volume
26-07-24 US$0.7940 -6.19% 1,063,132
26-07-23 US$0.8464 -5.92% 1,082,227
26-07-22 US$0.8997 -4.33% 496,587
26-07-21 US$0.9404 +1.71% 145,786
26-07-20 US$0.9246 +1.07% 299,499
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.7940USD
Average target price
6.000USD
Spread / Average Target
+655.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock